On July 9, WuXi XDC rose 3.34% in regular trading, trading at HK$60.4/share, with turnover of HK$40.96 million.

The rally was driven by positive analyst coverage from multiple investment banks. CLSA raised its target price from HK$80.9 to HK$82.6, maintaining an Outperform rating, forecasting strong new project growth in the first half and continued global ADC outsourcing market share gains. CLSA projects revenue growth of 33%, 31%, and 28% for the next three years, with net profit growth of 11%, 51%, and 33% respectively. Separately, Daiwa initiated coverage with a Buy rating and HK$78 target price, naming the company a top pick in Chinas CXO sector, noting its 24% ADC market share and full-chain CRDMO service capabilities.

Within the Life Sciences Tools and Services sector, the broader group showed strength. Among peers, Insilico rose 5.57%, WuXi Biologics rose 4.32%, XtalPi rose 2.86%, WuXi AppTec rose 2.73%, and Pharmaron rose 2.27%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)